Community-acquired pneumonia: A budget impact model;Polmonite acquisita in comunità: Un modello di impatto sul budget

Infezioni in Medicina

Volumn 18, Issue 3, 2010, Pages 143-153

  Giusti, Massimo ^a   Bamfi, Francesco ^b   Perrone, Francesco ^b   Pitrelli, Andrea ^b   Pippo, Lara ^b   Giuliani, Luigi ^c  

^a MOLINETTE HOSPITAL   (Italy)

^b GSK   (Italy)

^c Azienda Ospedaliera Universitaria Maggiore Della Carita   (Italy)

Author keywords

Budget impact model; Community acquired pneumonia; Switch therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFOTAXIME; CEFTRIAXONE; CLARITHROMYCIN; ERTAPENEM; LEVOFLOXACIN;

ANTIBIOTIC THERAPY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DRUG COST; HOSPITAL COST; HOSPITALIZATION; ITALY; MONOTHERAPY; TREATMENT FAILURE;

AGED; ANTI-BACTERIAL AGENTS; BUDGETS; COMMUNITY-ACQUIRED INFECTIONS; DRUG COSTS; DRUG THERAPY, COMBINATION; EQUIPMENT AND SUPPLIES, HOSPITAL; FEMALE; HEALTH CARE COSTS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INCIDENCE; INTENSIVE CARE; ITALY; MALE; MIDDLE AGED; MODELS, THEORETICAL; PERSONNEL, HOSPITAL; PNEUMONIA; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 78049458710     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Libanore M., Bicocche R., Pantaloni M., Antonioli M.P., Napoli N., Ghinelli F. Le polmoniti acquisite in comunità: appropriatezza dei ricoveri, fattori di rischio e terapia adottata. Infez. Med. 1, 34-43, 2004.
2. Potena A., Simoni M., Cellini M., et al. Management of community-acquired pneumonia by trained family general practitioners Int. J. Tuberc. Lung Dis. 12, 1, 19-25, 2008.
3. Fine M.J., Auble E.T., Yealy D.M. A prediction rule to identify low risk patients with community acquired pneumonia. N. Engl. J. Med. 336, 243-250, 1997.
4. Moine P., Vercken J., Chevret S., et al. Severe community-acquired pneumonia: etiology, epidemiology, and prognostic factors. Chest 105, 1487-1495, 1994.
5. Iori I., Gussoni G., Blasi F., et al. Linee-guida e gestione ospedaliera delle polmoniti acquisite in comunità: l'esperienza italiana dello studio FASTCAP. Italian Journal of Medicine 3, 4, 212-219, 2008.
6. Blasi F., Iori I., Bulfoni A. Can CAP guideline adherence improve patient outcome in internal medicine departments? Eur. Respir. J. 32, 4, 902-910, 2008.
7. Orrick J.J., Segal R., Johns T.E., et al. Resource use and cost of care for patients hospitalised with community acquired pneumonia. Impact of adherence to infectious diseases society of america guidelines. Pharmacoeconomics 22, 11, 751-757, 2004.
8. File T.M. Jr, Marrie T.J. Burden of community-acquired pneumonia in North America adults. Postgrad. Med.122(2), 130-141, 2010.
9. Ye X., Sikirica V., Schein J.R., Grant R., et al Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin. Ther. 30, 2, 358-371, 2008.
10. Bartlett J.G., Mundy L.M. Community acquired pneumonia. N. Engl. J. Med. 333, 1618-1624, 1995.
11. MacFarlane J. Community acquired pneumonia. Br. J. Dis. Chest 81, 116-127, 1987.
12. Pinner R.W., Teutsch S.M., Simonsen L., et al. Trends in infectious diseases mortality in the United States. JAMA 275, 189-193, 1996. (Pubitemid 26028558)
13. Centers for Disease Control and Prevention. Premature deaths, monthly mortality and monthly physician contacts-United States. MMWR Morb. Mortal. Wkly Rep. 46, 556-561, 1997.
14. Marston B.J., Plouffe J.F., File T.M., et al. Incidence of community-acquired pneumonia requiring hospitalizations: results of a population-based active surveillance 2004 study in Ohio. Arch. Intern. Med. 157,1509-1518, 1997.
15. ISTAT: Statistiche della Sanità - Anno 2000, n.6; Roma, 2001.
16. Del Prato B., Bettoncelli G., Neri M. In: Infezioni Respiratorie. Ed. Pacini 2001.
17. Viegi G., Pistelli R., Cazzola M., et al. Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. Respir.Med.100, 46-55, 2006.
18. Lazzaro C., Iori I., Gussoni G. Studio FASTCAP sulla gestione ospedaliera delle polmoniti acquisite in comunità: valutazione farmacoeconomica della fase prospettica. Italian Journal of Medicine 2, 1, 55-66, 2008. (Pubitemid 351839746)
19. Fattore G., Torbica A., Mangone M. Analisi dei costi di quattro strategie terapeutiche nella gestione di pazienti con broncopneumopatia (BPCO) moderata e severa: un'applicazione del metodo bootstrap. Pharmacoeconomics 7, 2,135-143, 2005.
20. Eandi M., Zaniolo O. Valore clinico ed economico di levofloxacina. Farmacoeconomia e percorsi terapeutici 7, 4, 223-237, 2006.
21. Athanassa Z., Makris G., Dimopoulos G., Falagas M.E. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs 68, 17, 2469-2481, 2008.
22. Bassi O., Zuccarelli S., Amalfitano M.E. Clinical and economic outcomes of empiric parenteral antibiotic therapy for pneumonia: a retrospective study of 1,032 hospitalized patients. J. Chemother. 10, 5, 369-374, 1998.
23. Blasi F., Bulfoni A., Concia E., et al. Attualità nella gestione delle infezioni delle basse vie respiratorie in medicina interna. Italian Journal of Medicine 4,1,1-78,2010.